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The human skull is a dynamic structure formed frommultiple bones
connected at the osteogenic edges by ﬁbrous joints, the cranial sutures.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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leads to craniosynostosis, a congenital disorder which causes cranial de-
formations and potential cognitive impairment. While the full etiology
remains clouded in uncertainty, several genetic mutations have been
elucidated and implicated in craniosynostosis. Several transgenic
models have been used for identifying the signaling mechanisms in-
volved in premature fusion. Recent ﬁndings have correlated ﬁbroblast
growth (FGF), bone morphogenetic protein (BMP), and wingless-type
integration site (Wnt) signaling in craniosynostosis and potential ther-
apeutic strategies have been established. This review largely focuses on
these signaling pathways but also includes an extensive analysis of the
role of the mechanical stimuli and the mechanosensory proteins
Polycystins in suture formation. We hypothesize that Polycystins play
a pivotal role inmechanosensation andmechanotransduction and func-
tion at an epistatic level along with the aforementioned pathways.
Polycystins could be of paramount importance as tools for diagnosis
and treatment either at an embryonic or postnatal level.
2. Cranial vault development
2.1. Human skull
The vertebrate skull is an exquisitely complex structure and is formed
from two main parts—the neurocranium and the viscerocranium. The
neurocranium surrounds and protects the brain and the sensory organs
(optic, olfactory, and otic). The viscerocranium includes the bones of the
face and the palatal, pharyngeal, temporal, and auditory bones [1]. This re-
view will focus on the neurocranium. The neurocranium is principally
formed from ﬁve bones, the paired frontal and parietal bones and the un-
paired occipital bone [2]. Initially, the development of the skull startswith
the superﬁcial migration of mesenchymal stem cell populations (MSCs)
from the embryonic epithelium to brain and surface ectoderm destina-
tions. MSCs are pluripotent cells that can differentiate into chondrocytes,
osteoblasts, myoblasts, and adipocytes [3].
2.2. Origin of craniofacial mesenchymal tissues
Craniofacial mesenchymal tissues have three origins: neural crest,
paraxial mesoderm, and lateral mesoderm [4]. Accumulating evidence
indicates that the bones are of mixed embryonic origin, arising from
neural or mesoderm crest. Neural crest cells (NCC) are pluripotent
cells that migrate from the embryonic epithelium and, once they
reach their ﬁnal destination, condensate into blastemas and differenti-
ate into several cell types thus forming craniofacial structures. Dysregu-
lation of their levels of proliferation or differentiation respectively leads
to congenital craniofacial disorders as reviewed in Mishina and Sneider
[3].
Initially, the craniofacial neural crest cells (CNCC) contribution was
investigated by performing chick–quail transplantation experiments.
These studies showed that the anterior calvarial bone is derived from
neural-crest whereas the posterior bone from paraxial mesoderm. Fur-
ther studies in a transgenic mouse that expresses a marker for neural
crest cells, using the Cre-lox system, have enabled researchers to label
genetically cell populations and trace their origin. More speciﬁcally,
murine transgenic reporter genemodels that labeled cell types with ga-
lactosidase under the Wnt1 promoter demonstrated that the skull is
formed from mesenchyme of two different origins, the mesoderm and
neural crest [5,6]. Therefore, the migration of neural crest cells was
further elucidated and demonstrated that parietal bones are of meso-
dermal origin, whereas the frontal bone is of neural crest in origin [7].
At the time of NCC migration, growth factor signaling via bonemor-
phogenetic proteins (BMPs), ﬁbroblast growth factors (FGFs), and
Wnts, as well as other signaling pathways, including Delta/Notch,
retinoic acid, Hedgehog (Hh), and their downstream targets, are in-
volved in cell fate determination, growth, differentiation, and survival
[1]. In particular, NCCs,which comprise the cranial region, play a distinctrole as they differentiate into osteoblasts and chondrocytes in addition
to other types of cells, and an imbalance in their portion can lead to se-
vere craniofacial anomalies, an example of such, craniosynostosis,
which will be further analyzed below.
2.3. Cranial sutures
Cranial sutures emerge as soon as the developing bones approxi-
mate [8]. Skull ﬂexibility is enabled by the presence of cranial sutures,
ﬁbrous structures separating the bone plates and human skull, essential
for the expansion and subsequent growth of the skull. The skull expan-
sion is perpendicular to the orientation of sutures during expansion.
Sutures constitute major bone growth sites and are regarded as com-
plexes, composed of the two osteogenic bone fronts, the mesenchy-
mal/ﬁbrous tissue of the suture, the underlying dura mater, and the
overlying pericranium [2].
Four cranial sutures separate the ﬁve cranial bones; the sagittal su-
ture exists between the two paired parietal bones, the coronal suture
between the frontal and parietal bones, the metopic between the two
frontal bones, and the lambdoid between the occipital and parietal
bones. This arrangement is similar to other species. With the exception
of the posterior frontal suture which closes at humans around
18 months of age, and similarly in mice in the ﬁrst 45 days of life, all
other sutures remain patent and unossiﬁed [2].
Two ossiﬁcation processes take place during cranial development,
intramembranous and endochondral ossiﬁcation. The distinct differ-
ence between these two processes is that during endochondral ossiﬁca-
tion a cartilaginous intermediate arises, whereas in intramembranous
ossiﬁcation, condensedmesenchyme cells directly differentiate into os-
teoblasts and form bone tissue without any cartilaginous precursor [9].
During intramembranous ossiﬁcation, osteoblasts secrete an extracellu-
lar matrix, consisting of type I and other forms of collagens and proteo-
glycans. Mineralization proceeds and the ﬂat bones of the skull expand,
from the skull base toward the apex of the cranium [2].
Ossiﬁcation of the skull is mainly via intramembranous ossiﬁcation
and is a procedure orchestrated by the suture mesenchyme and the
dura mater, the rigid membrane that adheres to the inner surface of
the vault and separates it from the brain. However, although skull
bones are ossiﬁed through intramembranous ossiﬁcation, suture fusion
can undergo both types of mineralization. Themesenchymal cells of the
suturemesenchymeproliferate and differentiate into osteoblasts during
cranial expansion that deposit collagen ﬁbers and minerals to the bony
osteogenic ends to increase their size. Ossiﬁcation can also be accom-
plished under mechanical stimuli, when the cells lying on osteogenic
fonts become bone through intramembranous ossiﬁcation [10] (Fig. 1).
Sutures being obviously less stiff than the bones they join may play
mechanical roles. Their ﬁbrous identity plays a pivotal role in various
procedures, such as resistance to tensile or compressive forces, during
the osteogenic expansion of the skull. In the skull, sutures are subjected
to three different types of strain. The strain is sensed by cells and in com-
parison to stress it can be measured [8]. Thus, sutures are bone growth
sites which respond to biomechanical signals which are induced by the
underlying brain. These signals are translated into cell signaling at su-
tures, resulting in the transcription of osteoblast differentiation, thus
bone ossiﬁcation [11].
Forces that are sensed and absorbed by sutures include sudden
forces such as sudden impacts, cyclic loadingwhich involves blood ves-
sels pulsation [12], feeding, locomotion and quasi-static loading due to
tensile strains caused by internal organ pressure, intracranial pressure
or forces implemented by the dura mater [8]. Dura mater has been
found to play a vital role in suture patency and fusion. Studies have
found that sutures devoid of dura mater, respond with fusion [13].
Thus, dura mater and its underlying growth and paracrine factors may
regulate suture patency and fusion.
Several studies have imposed extrinsic forces such as an orthodontic
spring on sutures of the palate. Tensile loadsweremainly used, owing to
Fig. 1. The cranial suture complex. The cranial suture complex is composed of the two osteogenic bone edges, the suture mesenchymal tissue and the underlying dura mater. A: The
mesenchyme at rest consists of undifferentiated cells and collagen ﬁbers which are at a parallel state. B: When force is implemented, the collagen ﬁbers adopt different orientations
and the mesenchymal cells differentiate into various cell types (osteoblasts, osteoclasts, osteocytes); bone homeostasis is regulated by both osteoblasts and osteoclasts. Osteoblasts
through intramembranous or endochondral ossiﬁcation form bone at the suture osteogenic fonts and the human vault expands; osteoclasts mediate bone resorption; osteocytes
remain buried in the bone matrix of the cranial vault.
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also applied. Because of force imposition, cell and molecular reactions
were observed. In rats and mice, static tensile loads have been applied
in vivo to the sagittal suture resulting in differential growth during
fetal and infant life. An optimal energy absorption and stress transfer
are correlated to well-oriented collagen ﬁber sutures and a higher hier-
archical suture cell morphology [14].
In terms of morphology, this strain causes an elevation in suture
width and cell changes such as changes in size, number, and vascularity.
In addition, an increased osteoid production leads to mineralization at
the osteoid fronts and an increased matrix production suggesting that
2 weeks stretching of mouse sagittal sutures causes up-regulation of
the osteogenesis factors alkaline phosphatase and osteopontin [15]. In
addition, another in vitro study detected that force led to the premature
fusion of sagittal suture, further connecting craniosynostosis to epige-
netic factors [16].
Sutures also maturate and form ﬁbered structures that resist static
tensile strains due to intracranial pressure, absorb cyclic loading during
mastication and locomotion, and act as shock absorbers during external
effects such as brain traumas. The study of their complex nature, formed
from a range of extracellular matrix zones, different cell populations,
and a distinct vasculature, is complicated, as all these parts respond
differently to mechanical stimuli. The same applies for the periodontal
ligament (hPDL), the connective tissue between the tooth and alveolar
bone, which is, in fact, a suture.
Due to expansion, a decrease in suture stiffness has been observed
further highlighting the interaction between increased loading and
osteogenic response. Taking the aforementioned data together, it is
suggested that cyclic forces, either in tension or compression, induce
sutural changes and skull modeling [17].
Although cranial sutures initially remain thin and straight between
bones, they become interdigitatedwith age. As a result of the interdigita-
tion of sutures, the application of force to one area of a suture can cause
stresses of different origin and at various areas of the same suture. This
complex and different forces can lead to different movements in the su-
tures that can result in a complete displacement of the suture [18].Math-
ematical models have demonstrated this behavior by employing
different models of mechanical stimulus and time-dependent processes.
Skull expansion and suture growth involve cell signaling pathways,which are likely controlled by secreted paracrine factors and responsive
to differently implemented mechanical stimuli [19].
2.4. Craniosynostosis
During development, cranial sutures need to remain patent, while
allowing rapid bone formation at the edges of the bone fronts [20]. If os-
siﬁcation is not synchronized, and there is failure of the signaling path-
ways to maintain suture patency, then functional impairment can be
caused, a prime example of which is craniosynostosis.
Craniosynostosis, with a birth prevalence of 1:2000–2.500 live births,
is heterogeneous in its presentation and can be classiﬁed into two
categories, syndromic and non-syndromic [1]. The premature clo-
sure of sutures is associated with a distorted skull shape, with elevat-
ed intracranial pressure, visual and respiratory impairment, and
neurological dysfunctions such as inhibited intellectual ability. Epi-
demiological data have correlated craniosynostosis with multiple
pregnancies, prematurity, high birth weight, and elevated paternal
and maternal age [21].
Non-syndromic craniosynostosis accounts for 70% of the cases and
occurs when the main defect in the individual is fused sutures. On the
contrary, syndromic craniosynostosis is associated with further mor-
phological manifestations. Frequencies of different types of craniosyn-
ostosis vary, but in general sagittal synostosis is the most common
(40–55%), coronal (20–25%), metopic (5–15%), multiple suture synos-
tosis (5–15%), and lambdoid (0–5%) [22].
Despite the genetic etiology of several forms of craniosynostosis,
there are several epidemiological factors, either extrinsic or intrinsic,
that lead to the premature fusion of the suture. The effect of the me-
chanical strain transmitted by the growing brain to maintain suture
patency, chromosomal abnormalities of genes related to osteogene-
sis, as well as extrinsic forces applied to the skull, may contribute
to the manifestation of craniosynostosis. Craniosynostosis has been
reported as a clinical feature in many syndromes, the most common
of which include Apert, Saethre–Chotzen (SC), Muenke, Crouzon
syndromes [1].
At a genetic basis, craniosynostosis has been linked to mutations of
several osteoblastogenic molecules including the ﬁbroblast growth fac-
tor receptors (FGFRs), homeobox protein MSX-2 (MSX2), Ephrin-B
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factor 2 (RUNX2). Some of these genes have been elucidated from rare
craniosynostosis syndromes such as Boston-type craniosynostosis
(MSX2), Saethre–Chotzen syndrome (haploinsufﬁciency of the Twist
nuclear transcription factor gene) as reviewed in Twigg and Wilkie [1].
Currently, craniosynostosis can be treated surgically, an intervention
that remodels the skull and creates extra space for the brain to develop.
As a number of signaling pathways, cytokines and growth factors have
been correlated to suture patency, a further understanding of their func-
tion could lead to the development of innovative translational treat-
ment methods [23].
2.5. Mechanical forces and skull expansion
Mechanical forces can be from an external (stretch, sound, breath-
ing, mastication, swallowing) or an internal source (ﬂuid ﬂow, blood
pressure, osmotic pressure, heart pulsation) and according to the cell
type that are applied may vary in intensity [24]. The fact that the
mechanical stress is translated into a biochemical response by the cell
implies that there is an interaction between the extra cellular matrix
(ECM) and the internal cytoskeleton. The cytoskeleton is resistant to
tensile and compressive forces due to the existence of microtubules
and microﬁlaments. Stress-based deformation of the ECM alters the cy-
toskeleton and deforms the cell through stress applied at focal adhesion
sites [25].
Growth and development are the net result of environmental ad-
justment of genetic inheritance. Sutures are composed of mesenchymal
cells which ultimately differentiate into chondrogenic, osteogenic, and
ﬁbrogenic cells. The fate of these cells is inﬂuenced by genes and envi-
ronmental factors, including mechanical forces. Mechanical forces
form bone and regulate cartilage formation by regulating gene expres-
sion, differentiation, maturation, and other signaling pathways [26].
Mechanical forces can cause deformation of the cell membrane or
the cytoskeleton by evoking changes in cell signaling pathways impli-
cated in cell differentiation, proliferation, and the production of extra-
cellular matrix molecules. Notably, an ideal mechanical force is
considered to be theminimum force that causes themaximummineral-
ization in the shortest time period [27]. In addition, according toWolff's'
law, bone remodeling is accomplished because of the mechanical de-
mands it has to withstand [18].
During skull expansion, cranial sutures play a fundamental role in its
proper expansion and development, as its cells of mesenchyme origin
sense forces, and according to its tension, induce mineralization of the
cranial bones. Mechanosensing involves interaction of various protein
compounds including integrins, actin microtubules, and adherent junc-
tions. Many of these proteins are connected to signaling pathways,
which induce calcium signaling or other pathways [28]. Interestingly,
the term “Suture mechanobiology” is used to support the importance
of the mechanical stimuli that are capable of regulating sutural growth
and their translation into signals which contribute to biological growth
[29].
2.6. Polycystins and mechanical stimuli
The protein family of Polycystins (PCs) is implicated in
mechanosensing, as it has been shown that polycystins interact
with many mechanosensing compounds. Polycystins 1 and 2
(PC1, PC2) have been reported as key mechanosensor molecules
implicated in severe structural abnormalities (cysts formation, aneu-
rysms) as well as colorectal cancer and atherosclerosis [30–32]. In addi-
tion, they have been implicated in various processes, including renal
ﬂow sensing, vascular pressure and ﬂowmechanosensation, brain injury,
skeletal development, and osteoblast differentiation. PCs are integral pro-
teins expressed in human tissues, including kidneys, blood vessels, pan-
creas, liver, and the skull. They are localized in the primary cilium, at theplasma membrane, and at the endoplasmic reticulum (ER), where they
interact with various partners and trigger signaling transduction [30].
PC1 was ﬁrst identiﬁed by positional cloning as a gene mutated in
85% of patients with autosomal dominant polycystic kidney disease
(ADPKD) and its role in renal pathology and kidney development has
been intensively studied. PC1 (460 kDa) is an 11-segment integral
membrane protein, which constitutes a long N-terminal extracellular
region and a short intracellular C-terminal region of 200 amino acids.
PC1 interacts with its partners through protein motifs localized on its
N-terminus, including ﬂanked leucine-rich repeats (LRRs), Ig-like do-
mains (ILDs or PKD repeats), a G-protein-coupled receptor proteolytic
site (GPS), and a C-lectin-like domain (CLD). Interestingly, a study
which analyzed the mechanical identity of the PC1 N-terminus, using
single molecule force spectroscopy, showed that PC1 is characterized
by extensibility due to the unfolding/refolding of its Ig domains. Thus,
this trait may be essential for cell elasticity and cell signaling [33,34].
In addition, such binding sites, involve PC1 in protein–protein inter-
actions, including ligand-binding sites, implicating that it participates in
interactions that take place in the extracellular environment. PC1 is a
promising candidate in mechanotransduction as it spans the cellular
membrane and connects the extracellular matrix with the cytoskeleton
and intracellular signaling pathways [30].
More interestingly, PC1 is found localized at the primary cilium and
at the plasma membrane being involved in interactions between pro-
teins and between protein-carbohydrates. PC1 has been reported to in-
teract with proteins localized at adhesion points, adherent junctions,
and desmosomes. PC1 mediates cell-to-cell adhesion and intercellular
interactions and a small intercellular domainwhich is implicated in sig-
nal transduction by activating cytoplasmic effectors. The intracellular C-
terminal has been reported to be implicated in signal transduction in
several signaling pathways including JAK–STAT, the mammalian target
of rapamycin (mToR), the Wnt, the activator protein 1 (AP-1), and the
calcineurin–Nuclear factor of activated T-cells (NFAT) pathway [30,35,
36].
Polycystin 2 (PC2, TRPP2, 110 kDa) is also a six-segment transmem-
brane spanning integralmembrane. Both theN- andC-termini are intra-
cellular. The C-terminus contains a calcium-binding EF-hand domain
(EF), an endoplasmic reticulum (ER) retention domain, and a coiled-
coil domain (CC) and the N-terminus contains a ciliary sorting motif
(CSM). PC2 is located in the ER [37]. PC1 is required for the translocation
of PC2 from the ER to the nucleus [38]. PC2 is a member of transient re-
ceptor (TRP) channel family proteins. It has been shown that PC2 inter-
acts with cytoskeletal proteins as well as other mechanosensitive ion
channels in different cells, including potassium-selective stretch-
activated potassium channels and non-selective cationic SAC channels.
In a model where PC2 was knocked down with the use of siRNAs, it
was reported that PC2 mediates cell-to-cell adhesions partially through
E-cadherin [38].
Recent studies have correlated mechanical forces to biological re-
sponses. In a recent study, using an optimal tissue culture system for ap-
plying short-term mechanical stretching on pre-osteoblastic cells
derived from human periodontal ligament tissue (hPDL), was demon-
strated that PC1 modulates osteoblastic gene transcription and bone
cell differentiation through the calcineurin/NFAT signaling pathway
[35]. Another study has shown that PC1/PC2 is a ﬂow-tensing protein
complex in endothelial cells, responds to shear stress, and induces cell
proliferation changes leading to atherosclerosis [32].
2.7. Molecular mechanisms and craniosynostosis
2.7.1. FGF signaling
A signal transduction cascade is based on a ligand-dependent dimer-
ization of growth factor receptors. Dimerization brings the intracellular
tyrosine kinase domains into proximity, leading to autophosphorylation
on tyrosine residues, initiating phosphorylation events. The subsequent
activation of downstream targets results in the transmission of signals
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FGFRs are tyrosine kinase receptors that contain three extracellular
immunoglobin-like domains (D1–D3), one hydrophobic transmem-
brane domain and one cytoplasmic tyrosine kinase domain. In general,
mammals comprise 18 FGF types,which have been grouped into six dis-
tinct subfamilies, based on sequence homology and phylogenetic analy-
sis reviewed in [39].
FGFs are growth factor receptors that, once activated, mediate vari-
ous signal pathways implicated in multiple developmental processes.
FGFs play a fundamental role in cellular proliferation,migration and dif-
ferentiation, mitogenesis, angiogenesis, embryogenesis, and wound
healing. FGFs signal through cell surface FGF receptor (FGFR) Tyr ki-
nases, encoded by four distinct genes in mammals (FGFR 1–4). FGFs
bind to FGFRs, which brings the intracellular receptor kinase domains
into close proximity, such that phosphorylation, and hence activation
of the kinases can occur. The activated receptor kinases, thereafter,
phosphorylate and activate intracellular substrates, such as FGFR sub-
strate 2a (FRS2a) and phospholipase Cγ1 (PLCγ1). The activated
FRS2a substrate initiates the downstream signaling pathways, the
RAS–MAPK pathway or the PI3K–AKT pathway, whereas the activation
of PLCγ1 leads to calcium release and activation of protein kinase C
(PKC).
The RAS/MAPK kinase pathway affects cellular proliferation and
differentiation. Examples of MAP kinase effectors include c-Jun.-N-
terminal kinase (JNK), extracellular signal-regulated kinase (ERK),
and p38 mitogen-activated kinase. FGF signaling pathway also
interacts with the Wnt canonical pathway and is crucial for the dif-
ferentiation process of mesenchymal cells either to osteoblasts or
chondroblasts [39,40].
Mutations in FGF ligands are autosomal dominant forms and have
been associatedwith different craniosynostosis syndromes. FGFRmuta-
tions affect the ligand-binding domain afﬁnity, resulting in decreasing
receptor speciﬁcity or increasing receptor activity [41–45]. Several
point mutations in FGFRs have been identiﬁed and related to craniofa-
cial malformations.
Mutations in FGFR2 (S252T and P253R), account for the major-
ity of Apert, Crouzon, and Pfeiffer syndrome cases. All exhibit a
characteristic Crouzon-like facial appearance, with protruded
eyes, shortened face, and premature fusion of the coronal sutures
[22]. Analysis of bone marrow samples indicated proliferation of
osteoprogenitor cells in these tissues, implicating FGF in the early
stages of embryogenesis.
Apert syndrome patients share characteristics, such as biocoronal
synostosis and syndactyly of the hands and feet. Other cases have
been reported with cleft palate, and learning disability. Nearly all
Apert syndromemutations arise de novo and have been shown to orig-
inate exclusively from the father [46].
Mutations in FGFR1 (P252R) are associated with Pfeiffer syndrome
[47], and changes in FGFR3 (P250R) have been linked to Muenke syn-
drome [48]. Pfeiffer syndrome is characterized by broad, deviated
thumbs. Crouzon syndrome is usually the mildest of the FGFR2-
associated disorders and the clinical diagnosis is suggested by the com-
bination of crouzonoid faces and absence of major abnormalities of the
hands and feet. The distribution of mutations causing Pfeiffer and
Crouzon syndromes in FGFR2 overlaps considerably [46].
Several translational animal models have been established using the
aforementioned mutations. Deletion of both FGFR1 and FGFR2 genes
leads to lethal phenotypes.Micewith FGFR2 (Cys342Tyr)missensemu-
tation generated by Eswarakumar and colleagues demonstrated a
Crouzon phenotype [49]. A mouse model carrying an FGFR1 gain of
function mutation P252R, related to Pfeiffer syndrome has also been
studied, with a premature fusion noted inmultiple sutures. This pheno-
type exhibited premature and coronal suture fusion, midface hypopla-
sia, and facial asymmetry [50]. Increased bone ossiﬁcation further
supported that FGFR1 is important in osteoblast differentiation. Of all
the FGF receptors, FGFR2 seems to be most implicated in suture fusion[51]. FGF2 has been identiﬁed in duramater, by immunohistochemistry,
during suture fusion. In further studies, an increase in FGF2 mRNA in
translational models, by using a viral vector, causes premature suture
fusion [52].
2.7.2. TGF-β/BMP signaling
Organmurinemodel systems of cranial sutures have allowed for the
deﬁnition of TGF-β (transforming growth factor beta) as a potential reg-
ulator of suture fusion or patency. TGF-β is not associatedwith a known
form of craniosynostosis, but a series of studies by Opperman et al.
demonstrated that TGF-β1, β2, β3 are expressed in sutures and the
dura mater [53–55]. More speciﬁcally, TGF-β2 seems to promote suture
fusion and TGF-β3 patency.
In a tissue analysis from sutures of human infants, either synostotic
or controls, elevated TGF-β immunoreactivity was found in fused
sutures. Also, TGF-β has been correlated to its downstream ERK1/2
pathway as application of an ERK1/2 inhibitor disrupts the expression
and phosphorylation of TGF-β in a fused suture [56].
BMPs (bonemorphogenetic proteins), anothermember of TGF-β su-
perfamily, have been reported to induce osteogenesis and regulate a va-
riety of clinical disorders, such as cancer, skeletal and vascular diseases.
BMPs have also been implicated in suture fate, as studies have localized
BMP2, BMP4 in both fused and patent sutures. A recent study of patients
with non-syndromic sagittal synostosis highlights the importance of
BMPs in craniosynostosis. Genome-Wide Association analysis identiﬁed
single nucleotide polymorphisms (SNPs) in a region downstream of
BMP2 and BBS9 [57]. BMP2 plays a vital role in mesoderm formation
during embryogenesis and BBS9 is a component of protein aggregation
that has been correlated to craniosynostosis. BBS9 is part of a protein
complex which induces the moving of cargo molecules in and out of
cilia. Cilia act as a platform onwhich signaling pathways take place [57].
BMPs bind to type I and II transmembrane serine/threonine recep-
tors. When both receptors are present, the binding afﬁnity increases
dramatically. Activated BMP receptors, initiate signaling by phosphory-
lating downstream targets, Smad1, Smad5, and Smad8 proteins, which
then interact with Smad4 and translocate into the nucleus. BMP signal-
ing is regulated by extracellular and intracellular modiﬁers. Extracellu-
larly, BMP signaling is regulated by the cell surface in compliance with
secreted molecules. These include noggin and heparin sulfate pro-
teoglycans, such as glypicans [58]. Noggin is expressed in non-
fused sutures and over-expression of Noggin prevents fusion of
the posterofrontal suture that normally fuses by postnatal day 45.
Noggin is a BMP antagonist, known to be important for suture
patency.
Warren et al. found that the differential expression of the BMP an-
tagonist Noggin was responsible for the sutural fate. In sagittal and cor-
onal sutures that remained patent Noggin inhibited the signaling
capacity of BMPs. In contrast, Noggin when absent in fused sutures,
allowed BMP activity [59].
MSX1 and MSX2 are transcription factors which belong to genes
encoding homeodomain proteins, a class of transcriptional regulators
that play important role in development.MSX1/MSX2were originally iso-
lated by homology to the Drosophila msh (muscle segment homeobox)
gene. MSX2 is located on a locus on chromosome 5 and is regulated by
BMP-SMAD signaling. A single amino substitution in the homeodomain
of the humanMSX2 gene is associatedwith the autosomal dominant dis-
order Boston-type craniosynostosis [60]. Enhanced expression ofMSX2 in
mice increases bone growthof parietal bones into the sagittal suture anda
subsequent increase in osteoblastic cells is observed [61]. Additionally,
MSX1−/− homozygotes manifest a cleft palate model and abnormalities
of the frontal and parietal bones [62]. Recent studies have further eluci-
dated their function. MSX1/MSX2mutant mice exhibited a distinct retar-
dation in the migration of neural crest-derived cells and a subsequent
disorganization of neural patterning [63]. Recent ﬁndings have observed
inmutantMSX1/MSX2mice ectopic bone in the frontal foramen. This for-
mation of ectopic bone is associated with elevated BMP signaling [64].
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The Wnts (wingless-type integration sites) are a large family of
secreted glycosylated proteins that consists of 19 members present in
mammals. Wnt signaling pathway is one of the most conserved molec-
ular pathways, which controls several cellular processes, cell prolifera-
tion, differentiation, migration, as well as the patterning of cranial
neural crest cells, as reviewed in Logan and Nusse [65]. It has been re-
ported thatWnt signaling is important for the proliferation of the neural
crest-derived mesenchyme [66]. Deﬁciency of Wnt signaling, either by
low-density lipoprotein receptor-related protein 6 (Lrp6) deletion or
with mutated Wnt3/Wnt9 antagonists, resulted in facial clefts and
abnormalities in midfacial development [67].
Wnts signal through the canonical β-catenin pathway and also
through two non-canonical pathways, the Wnt/Ca2+ and the planar
cell polarity pathway. It is believed that all pathways are involved in
craniofacial development. The canonical pathway is regulated by β-
catenin.WhenWnt ligands bind to Frizzled (FZD) receptors, a cytoplas-
mic accumulation of β-catenin is triggered, which leads to its transloca-
tion into the nucleus. In the nucleus, β-catenin binds to lymphoid
enhancer factor/T cell transcription factor (LEF/TCF). This binding acti-
vates downstream transcription. The Wnt/Ca2+ pathway is character-
ized by an intracellular calcium release, possibly via G-proteins. This
pathway is also composed of activated phospholipase C and protein
kinase C (PKC). The planar cell polarity pathway is implicated in the
migration of cells within the palatal shelves. Thus, a crosstalk between
these canonical and non-canonical pathways may regulate the Wnt
signaling as reviewed in Baron and Kneissel [68].
β-catenin is a central signaling component of the canonical Wnt
signaling. Disruptions of β-catenin in neural crest cells result in lack of
skeletal structures and elevated neural crest cell differentiation. β-
catenin is essential in determiningwhether cells of mesenchymal origin
will differentiate into osteoblasts or chondrocytes regardless of regional
destinations [69]. On the other hand, activation of β-catenin causes an
increase in mesenchymal cells and an elevated presence of immature,
undifferentiated osteoblasts [70].
Axin2, however, acts as a negative regulator of the canonical Wnt
pathway, by promoting degradation of β-catenin [71]. Axin2, in
Axin1−/− mice, is expressed in the osteogenic fronts and periosteum
of developing sutures. Targeted disruption of Axin2 inmice induces pre-
mature fusion of cranial sutures, through an enhanced differentiation of
osteoprogenitors, thus an accelerated osteoblast proliferation and an ul-
timate mineralization [72]. It was mentioned earlier that the PF suture
in the mouse fuses through endochondral ossiﬁcation by postnatal day
45 and is ightly regulated by canonical Wnt pathway process. Recent
studies used an Axin2−/−mouse model and investigated PF sutures. It
was shown that PF sutures lack psychological endochondral ossiﬁcation
and are characterized by patency. These ﬁndings were further correlat-
ed to BMP signaling. In Axin2mutants, BMP is up-regulated, functioning
as a positive feedback mechanism [73]. This mechanism results in a
change of the cellular localization of β-catenin, which localizes towards
a membrane fraction, which enables cell–cell interactions during skull
formation. An ectopic cartilage was also found, which probably led to
the delayed suture fusion.
TWIST is a basic helix–loop–helix transcription factor and is located
on chromosome [74]. Mutations in TWIST cause Saethre–Chotzen syn-
drome [74]. Patients with Saethre–Chotzen syndrome, demonstrate
coronal craniosynostosis, facial asymmetry, limb abnormalities, and ear
crura [75]. The TWIST protein is thought to participate in osteoblast dif-
ferentiation and proliferation, as it is expressed in the osteoprogenitor
cells within the sagittal and coronal sutures [46]. In homozygous mice,
deletion of TWIST is lethal as they died at embryonic day 11.5. Their
prominent phenotype was due to failure of cranial sutures to fuse [76].
This study implied that TWIST regulated the patterning and fate of neural
crest-derived cells. Thus, a following study produced a heterozygous loss
of function mutation in the TWIST gene, in a murine model. TWIST het-
erozygous mice showed coronal fusion, resembling the Saethre-ChotzenSyndrome in humans [77]. It should be pointed out that a variety of
mutations, nonsense, missense, insertions, and deletions in Saethre–
Chotzen syndrome patients, have been found in the coding region of
the TWIST gene. Also, the Notch ligand Jagged1 is thought to be a down-
stream target of TWIST, as TWISTmutants demonstrate a decreased Jag-
ged1 expression. Conditional knockout of Jagged1 leads to coronal
craniosynostosis [78].3. Signaling interactions in cranial sutures
The craniofacial skeleton includes the neurocranium and facial
bones, which undergo intramembranous and endochondral ossiﬁca-
tion, respectively. The aforementioned signaling pathways are all in-
volved in the regulation of its development and growth. A delicate
balance exists between proliferation and differentiation in maintaining
the anatomy of the cranial sutures. FGF, BMP, and Wnt signaling,
along with their downstream or upstream targets, are critical players.
Signals from the dura mater may also regulate the maintenance of su-
tural patency prenatally, whereas signals in the osteogenic fronts dom-
inate after birth, suggesting that polycystinsmay act asmechanosensors
and trigger the signaling cascade at a postnatal level. Indeed, the under-
standing of the signaling networks that control the commitment and
differentiation of suture mesenchyme cells will not only expand our
basic knowledge of themolecularmechanism of cranial suture develop-
ment but will also aid our ability to develop therapeutic means of inter-
vention in craniosynostosis.
FGF signaling is present both in endochondral and intramembranous
bones and regulates their development reviewed in Marie [79]. FGF2,
FGFR1, and FGFR2 have been found in the cranial vault during embryo-
genesis [46,80]. The morphology and patency of sutures are regulated
by the presence of FGFR1 and FGFR2, which act in parallel with other
osteogenic-related genes. It was shown that if FGF2 is applied to the os-
teogenic fonts via beads, ossiﬁcation is accelerated. A subsequent study
which blocked FGF2 with neutralized beads revealed that osteogenesis
was induced, implicating an FGF2 role in bone formation. FGF signaling
has been integrated with activation of the transcription factor TWIST,
which causes craniosynostosis via haploinsufﬁciency [81]. On the con-
trary, FGFs cause craniosynostosis due to gain-function mutations [82].
Haploinsufﬁciency of the transcription factor TWIST1 is associated
with SC syndrome and is manifested by craniosynostosis. It was
shown that the TWIST forms heterodimers with ubiquitously expressed
inhibitor of DNA-binding/differentiation proteins (bHLH) (T/E) and
homodimers (T/T), can have different functions. More speciﬁcally, this
study supported the hypothesis that T/T reside at the osteogenic fonts
and T/E in between sutures. The formation of dimers throughout the su-
tures interferes in other pathways related to suture patency. For exam-
ple, T/T dimers up-regulated FGFR2 expression, resulting in increased
FGF signaling, and a subsequent increase in BMP signaling through
binding to SMAD proteins. T/E dimers, on the other hand, up-regulate
thrombospondin 1 (TSP1) expression, which activates TGF-β [83]. De-
pending on the TGF-β isoform, this can lead to suture patency or fusion.
Further studies, proved that mice TWIST homodimers resulted in
elevated FGFR2 levels, which ultimately resulted in craniosynostosis.
In the same study, the authors demonstrated that in heterodimer
Twist mice, suture fusion could be inhibited by limiting FGF signaling
[84]. Obviously, it can be inferred that if craniosynostosis is due to an ini-
tiatingmutation in a relevant gene, then inhibition of a relative signaling
pathway could hinder suture fusion.
Wnt signaling plays a pivotal role during osteogenesis, as it both pro-
motes the differentiation process of the precursor cell population and
the commitment of these cells to the osteoblast lineage. Conditional β-
catenin deletion in the head results in replacement of the cranial vault
by cartilage as well as in reductions in osteogenic factors, such as
RUNX2 mRNA levels [85]. It is apparent that β-catenin regulates target
gene expression.
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β-catenin activates both TWIST1 in vitro and TWIST2 in vivo, identifying
them as nuclear targets [86,87]. Furthermore, TWIST1 inhibits chondro-
genesis in vitro, suggesting that TWIST1 could repress chondrogenesis
in vivo [87].
TWIST1 is a requisite in early migration and survival of cranial mes-
enchyme populations, which formulate the skull bones. A study by
Yoshida and colleagues showed that during the establishment of the
coronal (COR) suture area, TWIST is responsible for the regulation of
the sutural mesenchyme and its subsequent osteoblast differentiation.
These authors showed in calvarial organ culture, where they inhibited
TWIST using morpholino-antisense oligonucleotides that COR sutural
capacity was narrower, and its fusion was enhanced due to TWIST inhi-
bition [88]. Therefore, its presence along with the presence of signaling
pathways regulating skull formation at early migration stages plays a
pivotal role.
In further studies, Behr and colleagues, building on the previous ob-
servations, demonstrated that active canonical Wnt signaling is respon-
sible for cranial suture patency and that low levels of Wnt signaling
allow craniosynostosis to appear [89]. More speciﬁcally, they further
elucidated that the cranial fusion is attributed to chondrogenesis, a pro-
cedure normally inhibited by TWIST [89].Fig. 2. Signal transduction pathways in cranial development. The ﬁgure schematically illustrates t
impairment of these pathways can lead to premature cranial fusion thus craniosynostosis. FGF
hence activated and further activate intracellular substrates, which initiate downstream signa
to the nucleus where it interacts with the transcription factor ERF, which is then exporte
expression. TWIST also represses RUNX2 by forming a heterodimer with TCF12. Mutations
triggers the constant expression of ERK1/2, thus RUNX2 expression is not abrogated and oste
BMP signaling: BMPs bind to type I/II transmembrane receptors. Activated receptors initiate s
interact with Smad4 which translocates into the nucleus. BMP over-expression leads to the e
Noggin.Wnt signaling: The Wnts signal through the canonical β-catenin pathway. Wnts bind
the nucleus and binds to TCF/LEF transcription factors. Subsequent transcription of osteogenic
receptor; CK1, casein kinase 1; DVL, the scaffolding protein Disheveled; ERF, ETS domain-con
FGF4, ﬁbroblast growth factors 3,4; FGFR1/2/3, ﬁbroblast growth factor receptors 1/2/3; FRAT
low-density lipoprotein receptor-related protein 5/6; MEK, mitogen-activated protein kinas
TCF12, transcription factor 12; ΤGF-β, transforming growth factor beta; TGFβR, transforming
twist-related protein 1.Additionally, another component of Wnt-β-catenin signaling path-
way Axin2 is implicated in craniosynostosis. In a deﬁcient Axin2murine
model, mice exhibited skeletal abnormalities resembling craniosynos-
tosis in humans. A genetic disruption of Axin2 alters β-catenin [90]
and this, in turn, results in the induction of synostosis-osteoblast-relat-
ed genes, including the FGF–FGFR family, suggesting a potential link be-
tween FGF andWnt signaling. Also, it is reported that Wnt orchestrates
suture closure and skull development by maintaining a balance be-
tween FGF and BMP signaling.
MSX2 is a member of the homeobox gene family, whose transcrip-
tion is regulated by BMP and TGF-β. Mice over-expressingMSX2 devel-
op premature fusion of coronal and sagittal sutures. MSX2 and TWIST
function cooperatively in the processes of osteoblast differentiation
and proliferation. MSX2 is also related to BMP signaling, as it is regulat-
ed by BMP4which in turn is regulated by the canonicalWnt pathway in
other tissues. The fact that BMP antagonist Noggin is expressed in pat-
ent sutures further enforces the observation that BMP signaling is criti-
cal for regulating suture patency, and inhibited BMP signaling may
contribute to craniosynostosis (Fig. 2).
Cranial sutures in rats and mice have been used for biomechanical
studies, but limited information is available on the cellular andmolecu-
lar events inducedwhen such sutures are exposed tomechanical stress.he central signal transduction cascades implicated in cranial suture development. Possible
signaling: FGFs (FGF4, FGF3) bind to FGF receptor Tyr kinases; FGFRs are phosphorylated
ling pathways such as the RAS–MAPK pathway. The phosphorylated ERK1/2 translocates
d from the nucleus. Within the nucleus ERF can bind to RUNX2 and repress RUNX2
in FGFRs are associated with craniosynostosis syndromes, as over-expression of FGFRs
ogenesis occurs. TGF-β signaling: TGF-β signaling is correlated with downstream ERK1/2.
ignaling by phosphorylating downstream targets Smad1, Smad5, Smad8 proteins, which
xpression of RUNX2, thus to cranial fusion. BMP signaling is regulated by the antagonist
to FZD receptors and an accumulation of β-catenin is triggered. β-catenin translocates to
markers follows. BMP, bone morphogenetic protein; BMPR, bone morphogenetic protein
taining transcription factor; ERK1/2, extracellular signal-regulated kinase 1/2; FGF3 and
1 proto-oncogene; FZD, Frizzled receptor; GSK3-β, glycogen synthase kinase 3; LRP5/6,
e kinase; MSX2, homeobox protein MSX-2; RUNX2, runt-related transcription factor 2;
growth factor beta receptor; TCF/LEF, T cell factor/lymphoid enhancer factor; (TWIST),
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in vivo demonstrated that midpalatal force promoted cartilage forma-
tion [91]. PC1 and PC2 are promisingmechanosensorymolecules poten-
tially involved in this process since previous studies have shown their
implication in skeletogenesis [91,92]. It has been reported that PC1-
deﬁcient mice present restricted growth effects at the skull base and
in craniofacial sutures, without however knowledge of the underlying
molecular mechanisms [92]. Mice with ﬂoxed alleles of PC1 were
crossed with Dermo-1-Cre, Wnt1-Cre, and Osx-Cre delete strains, to
conditionally remove PC1.Mutant animals showed a premature closure
of the presphenoid and sphenooccipital synchondroses at the cranial
base [91].
Furthermore, conditional deletion of PC2 in neural crest-derived
cells provoked mice mutants which showed craniofacial deformities,
including mechanical trauma, fractured molar roots, distorted incisors,
alveolar bone loss, and compressed temporomandibular joints, in addi-
tion to abnormal skull shapes. It is worth mentioning that mutants
showed no indication of these phenotypes at embryonic stages, sug-
gesting that in utero heads do not receive signiﬁcant mechanical stress
[93].
Recent ﬁndings establish correlation between PC1 and β-catenin in
autosomal dominant polycystic kidney disease, where PC1 C-terminus
tail (CTT) undergoes cleavage and is released intracellularly. It has
been demonstrated that the CTT binds to β-catenin and co-localizes in
the nucleus. This has led to the view that CTT inhibits the ability of β-
catenin and Wnt ligands to activate the TCF gene. Loss of PC1, after
being silenced in MC3T3-E1 osteoblastic cell line by using lentivirus-
mediated shRNA technology, impaired mechanical strain, as PC1 deﬁ-
ciency resulted in the loss of ability to sense external mechanical stimu-
li, thus promoting osteoblastic proliferation and differentiation [94].
The importance of this effect could be clearly demonstrated in crani-
al suture development, as cranial sutures constantly respond to
mechanical stimuli. It has been shown that osteoblasts require the
mechanosensory molecule PC1 to respond to mechanical forces, by
enhancing osteoblastic mechanoresponse, through a potential PC1/β-
catenin action [94].
4. Polycystins and cranial sutures
Skeletal abnormalities had ﬁrstly been reported in PC1 deﬁcient
mice which had lethal phenotypes [95]. Then mice with ﬂoxed alleles
of PC1 were crossed with Dermo-1-Cre, Wnt1-Cre, and Osx-Cre delete
strains, so as to remove conditionally PC1. Mutant animals showed
a premature closure of the presphenoid and sphenooccipital
synchondroses at the cranial base [91] correlating the central role of
polycystins in cellular mechanosensation and mechanotransduction
processes.
PCs act as mechanosensory proteins in cranial development. Skull
expansion depends on tensile forces, thus, PC1 is a mediator as it con-
trols the proliferation of the sutural mesenchymal cells. In a Wnt-Cre,
Pkd1mouse model, PC1-deﬁcient mice displayed an impaired response
to tensile force. In this model, wild-typemice under inducedmidpalatal
suture expansion revealed ossiﬁcation at the bone joints, which was a
result of an intense proliferation, within the sutural mesenchyme.
Therefore, PC1 is related to osteoblast differentiation and bone
formation at sutural edges. Taking into account that recent studies
have reported that proliferation and differentiation of chondrocytes
and osteoprogenitor cells are modulated by mechanical stress [96], we
can speculate that PC1 can be implicated in this procedure.
For example, tensile forces applied across the frontonasal suture in
rabbits, led to the expansion of the craniofacial system [97]. Further-
more, in vivo cyclic and static loading of the cranial base of growing
rabbits, enhanced chondrocyte proliferation at synchondroses at the
cranial base [98]. However, the molecular mechanism underlying the
response of suture cells to mechanical strain remains poorly under-
stood. A hypothesis which we support is that PC1 is involved in theprocess of mechanotransduction and mechanoresponse during skull
growth.
According to studies by Hou B, it has been suggested that PC1 is
displayed on the surface of sutural osteoprogenitor cells and interacts
with the collagen ﬁbers, which are the internal part of the suture [91].
Collagen ﬁbers absorb tensile and compressive forces that are present
within a suture. Then, osteoprogenitor cells respond by proliferation,
osteoblast differentiation and subsequent bone deposition. This
model suggested by Hou B, in suture development, aligns with pre-
vious studies which implicate PC1 in osteoblast differentiation.
Most notably, a study by Xiao et al. further demonstrated that PC1
serves as a connection between cells and induces cell-to-cell adhe-
sions, acting as a mechanosensor protein, whose absence in vitro
led to skeletal abnormalities and decrease in RUNX2 levels [99].
Therefore, it is suggested that under the presence of PC1, expression
of the osteoblastic indicator RUNX2 is enhanced, an enhancement
which results in bone formation. Also, in the same studies, PC1 deﬁcien-
cy resulted in increased levels of phosphorylated ERK1/2. Hyper-
activation of ERK1/2 signaling pathway has been linked to premature
closure of the coronal suture and led to craniofacial malformations, as
elevated ERK1/2 led to a continuously active FGFR2 [100]. In addition,
in an in vivo model where ERK1/2 was inhibited, it prevented cranio-
synostosis [101]. Further studies have correlated PC1 deﬁciency with
increased proliferation and dedifferentiation of tubular epithelial cells
[102].
5. Therapies
Currently, themain treatment of craniosynostosis is surgery. An aim
would be to design therapies in craniosynostosis to prevent the rapid
refusion of the skull that occurs after surgery to separate the fused
bones, reducing the need for repeated surgery. Thus, some of the afore-
mentioned signaling pathways pose promising candidates for medical
treatment/diagnosis of craniosynostosis.
FGFR signalingpathway remains themost importantmolecule in the
pathological development of craniosynostosis, as mutations were ini-
tially found in FGFRs. Moreover, FGFR signaling is a critical player in os-
teogenesis. Treatments with FGFR inhibitors on osteoblast-like cells or
osteoblast cultures from coronal sutures of Apert syndrome have corre-
lated a non-properly working FGFR pathway to abnormal osteoblast
proliferation, differentiation, and apoptosis [103–106].
The ﬁrst study that characterized FGFR2 as a possible candidate was
byGreenwald et al. [106],who injected adenoviral vectors in rat sutures,
which either inhibited or enhanced FGF expression. In all calvarial
models, the posterior frontal suture fuses postnatally. In rats, to prevent
fusion of the posterior frontal suture, infection with a dominant-
negative FGFR1 construct, abrogated overactive FGFR signaling in vivo
[107]. Meaning that, when FGF was inhibited then suture patency was
maintained whereas, when enhanced, bone formation was triggered.
Also, mouse calvaria isolated from the Crouzon-like FGFR2C342Y
mousemodel cultured in the presence of FGFR tyrosine kinase inhibitor
PD173074 exhibited coronal suture patency. On the contrary, prema-
ture suture fusion was observed in untreated mutants [108].
Eswarakumar and colleagues reported in a Crouzon-like craniosynosto-
sis murine model system that substitution of two amino acids, L424A
and R426A, in the extracellular membrane domain of an activated
Fgfr2c, prevent the recruitment and tyrosine phosphorylation of
docking protein Frs2a, resulting in normal skull development [109].
In addition, a most promising study was conducted by Shukla et al.,
in which they cured mice with the Apert syndrome FGFR2 mutation by
intraperitoneally injecting an inhibitor of MEK1/2, the U0126, into the
pregnant mother. A subsequent postnatal fusion of the cranial sutures
was prevented. They proposed that themutant pups had a normal phe-
notype after birth, but their phenotypic responsewas unstable at a post-
natal level. It is highlighted that probably the dosage of the inhibitor or
its delivery may have led to this variability of response [101]. At this
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natal level may have altered the stability of the sutures. Therefore, PCs
can be implicated in the process. Further studies, in a similar model to
the Apert syndrome, showed that treatment with MEK1 inhibitor
PD98059 partially alleviated coronal suture fusion [100].
These data also suggested that the application of small molecule in-
hibitors may decrease FGFR tyrosine kinase activity and activate the
downstream target ERK1/2. These data may contribute to the develop-
ment of novel, non-invasive treatment options at a pre-birth level to
treat craniosynostosis. It was also proven that FGFR inhibitor can be
injected ectopically to prevent premature suture fusion and also
refusion of surgically corrected previously fused sutures, a recurrent
problem in treating craniosynostosis patients.
Glycosaminoglycans (GAG) regulate FGF/FGFR signaling. Thus, it has
been proposed that inhibitory GAGs that down-regulate FGF/FGFR sig-
naling could be potentially useful drugs for treating Apert syndrome.
More speciﬁcally, proteins like heparin sulfate and chondroitin sulfate
(CS) are involved in facilitation of FGF–FGFR ligand binding and osteo-
blastic differentiation. In this study, researchers manipulated levels of
GAGs and FGF ligands, and it has been illustrated that due to variable co-
operative binding activity, an inhibition of mutant FGFR signaling in
Apert syndrome was observed [110].
Other studies have used recombinant technology, using human anti-
bodies and small interfering RNAs (siRNAs). Noggin, an antagonist of
the BMP proteins, is expressed postnatally in the patent cranial sutures,Fig. 3. Schematic model of Polycystin 1 and Wnt signaling interaction. PC1 is an 11-segment inte
intracellular C-terminal part. Mechanical stimuli activate PC1, its C-terminal tail is cleaved an
then interacts with TCF/LEF transcription factor complex and initiates osteogenic gene expres
PC1 is inactive, Wnt remains silent, and FGF/BMP signaling pathways are induced and cause
CRDs, cysteine-rich domains; DVL, the scaffolding protein Disheveled; CLD, C-lectin like dom
glycogen synthase kinase 3; LDL-A, low-density lipoprotein receptor class A; LRP5/6, low-dens
PKD, polycystic kidney disease domain repeat; REJ, sea urchin sperm receptor for egg jelly; RU
WSC, cell wall integrity and stress response component.and the expression is suppressed by overactive FGF/FGFR signaling [59].
In a rat model transplanted with mutant FGFR2 osteoblasts, craniosyn-
ostosis was evident. In the abnormal fusing sutures, researchers found
a downregulation of Noggin. By application of recombinant human
Noggin, craniosynostosis was deterred [111]. In a following study, the
application of cells expressing exogenous Noggin was proven to be an
inhibitor of cranial synostosis in mice after the abrogation of the cranial
suture. Due to the fact that Noggin treatment inhibited bone formation,
Noggin therapymay be beneﬁcial to traditional surgical repair of cranio-
synostosis [112,113].
Several studies using human tissues or organ systems have shown
that fusion of cranial sutures may be related to an over-expression of
TGF-β2 [114,115]. In an in vivo study of a New Zealand white rabbit
model, with a bilateral coronal suture synostosis phenotype, the over-
expression of TGF-β2was obliteratedwith antibodies sharing neutraliz-
ing characteristics, in the synostotic sutures after surgery. In addition, in
further studies in which inhibitory TGF-β2 antibody was infused in a
collagenmatrix, inhibited postsurgical synostosis and improved volume
and craniofacial growth [116,117].
RNA interference has been used by recent studies, both in vitro [118]
and in vivo [101]. Gosain and colleagues used endogenous anti-TGF-β1
small interfering RNA to target and knockdown TGF-β1 mRNA tran-
scripts, which are expressed during cranial suture formation and may
affect FGFR signaling. Ultimately, a decrease in mRNA levels of FGF2
and FGFR1, as well as a successful knockdown of TGF-β1, was observed.gral membrane protein, which consists of an N-terminal extracellular region and a short
d translocates to the nucleus where it binds to β-catenin. The complex of PC1/β-catenin
sion therefore suture fusion. In the absence of mechanical cues, mechanosensory protein
acceleration of the premature suture fusion. CTT, C-terminal tail; CK1, casein kinase 1;
ain; FZD, Frizzled receptor; GPS, G-protein-coupled receptor proteolytic site; GSK3-β,
ity lipoprotein receptor-related protein 5/6; LRRs, leucine-rich repeats; PC1, polycystin 1;
NX2, runt-related transcription factor 2; TCF/LEF, T cell factor/lymphoid enhancer factor;
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which is responsible for suture fusion in vitro [118]. In vivo studieswere
also performed by using small hairpin RNA to target the mutant FGFR2
with the S252W mutation transcripts in the Apert syndrome mouse
model. A restoration of the wild-type phenotype was achieved. [101].
6. Concluding remarks—Outlook
Taken together, our hypothesis can be integrated into a schematic
model that incorporates PC1 and Wnt signaling (Fig. 3). We pose that
the extracellular N-terminal part of PC1 lies at the osteogenic fonts of
cranial sutures and acts as a mechanosensor that responds to external
cues applied on sutures. The PC1 C-terminal tail (CTT) undergoes
cleavage and is released intracellularly where it binds to β-catenin
in the nucleus. Wnt signaling is thus triggered resulting in activation
of TWIST, whereas FGF and BMP remain in an inactive state leading
to suture patency. In the absence of mechanical loading, PC1 is inac-
tive; Wnt remains silent, and FGF and BMP are over-induced and en-
hance premature suture fusion.
In conclusion, this review reinforces the important role of PC1 as a
key molecule that modulates mechanoresponses. PC1 can, therefore,
be potentially used as a diagnostic tool, suggesting that patients with
craniosynostosis may also share mutations in PC1/PC2 genes.
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